Which agent should be administered to reduce the risk of hemorrhagic cystitis when using Cyclophosphamide?

The correct agent to administer in order to reduce the risk of hemorrhagic cystitis when using Cyclophosphamide is Mesna. Cyclophosphamide is an alkylating agent that, when metabolized, can produce toxic metabolites that irritate the bladder and lead to hemorrhagic cystitis, which is characterized by bleeding and inflammation of the bladder.

Mesna, a sulfhydryl compound, functions by binding to these toxic metabolites in the urine, effectively neutralizing their harmful effects on the bladder lining. By doing so, Mesna helps to protect the urinary tract from damage and significantly reduces the risk of developing hemorrhagic cystitis in patients undergoing treatment with Cyclophosphamide.

Other agents mentioned, such as Dexamethasone, Atropine, and Amifostine, are used for different purposes in the context of cancer treatment and supportive care. Dexamethasone is a corticosteroid that may be used for its anti-inflammatory effects, Atropine is an anticholinergic that helps manage certain side effects, and Amifostine is a cytoprotective agent that is primarily used to reduce nephrotoxicity from cisplatin. None of these directly address the specific issue of bladder protection associated